Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells again...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Silvia Martini, Mariangela Figini, Aurora Croce, Barbara Frigerio, Marzia Pennati, Alessandro Massimo Gianni, Cinzia De Marco, Maria Grazia Daidone, Christian Argueta, Yosef Landesman, Nadia Zaffaroni, Alessandro Satta
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2020-10-01
סדרה:	Cells
נושאים:	TRAIL-R2 bispecific antibody selinexor survivin T cells
גישה מקוונת:	https://www.mdpi.com/2073-4409/9/10/2231
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!